WALTHAM, Mass. — January 7, 2026 — Leads & Copy — Dyne Therapeutics, Inc. (Nasdaq: DYN) announced that John Cox, president and chief executive officer, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on Wednesday, January 14, 2026, at 5:15 p.m. PT (8:15 p.m. ET).
A live webcast will be available in the Investors & Media section of Dyne’s website and a replay will be accessible for 30 days.
Dyne Therapeutics is focused on delivering functional improvement for people living with genetically driven neuromuscular diseases. The company is developing therapeutics that target muscle and the central nervous system (CNS) to address the root cause of disease. Dyne is advancing clinical programs for myotonic dystrophy type 1 (DM1) and Duchenne muscular dystrophy (DMD), and preclinical programs for facioscapulohumeral muscular dystrophy (FSHD) and Pompe disease.
At Dyne, their mission is to deliver functional improvement for individuals, families and communities.
Contacts:
Investors:
Mia Tobias
ir@dyne-tx.com
781-317-0353
Media:
Stacy Nartker
snartker@dyne-tx.com
781-317-1938
Source: Dyne Therapeutics
